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Background: Older patients with advanced chronic kidney disease (CKD) face the decision of whether to undergo
dialysis. Currently available data on this issue are limited because they were generated by small, short-term studies
with statistical drawbacks. Further research is urgently needed to provide objective information for dialysis decision
making in older patients with advanced CKD.
Methods: This nationwide population-based cohort study was conducted using Taiwan’s National Health Insurance
Research Database. Data from 2000 to 2010 were extracted. A total of 8,341 patients ≥70 years old with advanced
CKD and serum creatinine levels >6 mg/dl, who had been treated with erythropoiesis-stimulating agents were
included. Cox proportional hazard models in which initiation of chronic dialysis was defined as the time-dependent
covariate were used to calculate adjusted hazard ratios for mortality. The endpoint was all-cause mortality.
Results: During a median follow-up period of 2.7 years, 6,292 (75.4%) older patients chose dialysis therapy and
2,049 (24.6%) received conservative care. Dialysis was initiated to treat kidney failure a median of 6.4 months after
enrollment. Dialysis was associated with a 1.4-fold increased risk of mortality compared with conservative care
(adjusted hazard ratio 1.39, 95% confidence interval 1.30 to 1.49). In subgroup analyses, the risk of mortality
remained consistently increased, independent of age, sex and comorbidities.
Conclusions: In older patients, dialysis may be associated with increased mortality risk and healthcare cost
compared with conservative care. For patients who are ≥70 years old with advanced CKD, decision making about
whether to undergo dialysis should be weighted by consideration of risks and benefits.
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Older patients with chronic kidney disease (CKD) stage
5 comprise a rapidly growing emerging population that
may face the dilemma of whether to undergo dialysis or
receive conservative care [1]. Although patients with end-
stage renal disease (ESRD) tend to choose dialysis therapy
over conservative care, the use of dialysis to treat kidney
failure peaks in patients who are 75 years old and declines
thereafter [2,3]. The perceived financial burden of dialysis,
as well as a high comorbidity rate, uncertainty about the
treatment’s long-term benefit, and sense of life completion
and acceptance of death, leads many older patients to
forego dialysis [4]. The most critical concern of older
patients with CKD stage 5 is whether dialysis provides
benefits such as increased life expectancy and im-
proved functional ability at the end of life [5,6]. The
new guidelines of the Renal Physicians Association and
the American Society of Nephrology on the initiation and
withholding or withdrawal of dialysis emphasize shared
decision making with patients, their family members and
physicians in charge of their care [7]. Although compre-
hensive physician–patient communication may help to
achieve treatment goals and avoid unnecessary medical
expenditure [8,9], independent and objective evidence of
the comparative effectiveness of treatment options is still
needed to guide older patients’ decision making about
dialysis.
To date, very few studies have investigated the risks
and benefits of dialysis therapy for older patients with
advanced CKD. Previous studies examining this issue
found that dialysis conferred a significant but small ad-
vantage over conservative care in older patients [10-12].
However, the statistical power of these studies was lim-
ited due to small samples, short follow-up periods and
limitations of analytical methodologies. Because initi-
ation of chronic dialysis commonly occurs during follow
up in patients with advanced CKD, the use of appropri-
ate statistical methods to calculate the fraction of mor-
tality attributable to dialysis is essential. Accordingly, in
this nationwide population-based cohort study based on
Taiwan’s National Health Insurance Research Database
(NHIRD), we utilized the initiation of chronic dialysis as
a time-dependent covariate in Cox regression models to




The present study was performed using Taiwan’s NHIRD.
Taiwan launched the national health insurance (NHI) pro-
gram in 1995. This single-payer system covers approxi-
mately 99% of residents. In 1999, as part of the NHIRD
project, the Bureau of National Health Insurance began
to release patient data in electronic form for researchpurposes. These de-identified secondary data include all
registry and claims data, ranging from demographic data
to detailed orders from ambulatory and inpatient care.
Diseases are coded according to the International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM). The accuracy of diagnoses registered in the
NHIRD has been validated for several diseases, including
acute kidney injury [13], chronic kidney disease [14-16],
acute coronary syndrome [17], ischemic stroke [18] and
diabetes [19]. Because the dataset consisted of de-
identified secondary data, this study was exempted from
full review by the Institutional Review Board of Taipei City
Hospital (TCHIRB-1030407-W).
Study design
This population-based, observational, retrospective co-
hort study was performed to determine the association
between chronic dialysis and mortality in older patients
with advanced CKD. We identified all subjects ≥70 years
old in 2000 and extracted all relevant data for these sub-
jects for the study period of January 2000 to December
2010. These data included demographic characteristics,
diagnosis and procedure codes, drug prescriptions and
information about outpatient visits and hospital admis-
sions. We further extracted data from January 1995 to
December 1999 to ensure the availability of information
for all individuals for at least five years preceding enroll-
ment; this information was used to identify comorbidities.
Among all individuals ≥70 years old in January 2000 in
Taiwan, patients with ICD-9-CM codes for CKD (016.0,
042, 095.4, 189, 223, 236.9, 250.4, 271.4, 274.1, 403–404,
440.1, 442.1, 446.21, 447.3, 572.4, 580–589, 590–591, 593,
642.1, 646.2, 753 and 984) and receiving erythropoiesis-
stimulating agents (ESAs) were identified. The first date of
prescription of ESAs was defined as the index date. We
excluded patients with histories of cancer, patients receiv-
ing chronic dialysis or kidney transplantation before or
during the 30 days after the index date and patients with
follow-up periods <30 days. According to NHI reimburse-
ment regulations, patients with CKD, serum creatinine
levels >6 mg/dl (approximately equivalent to glomerular
filtration rate [GFR] <15 ml/min/1.73 m2), and hematocrit
<28% should receive ESAs to maintain a target hematocrit
level not to exceed 36%. In addition, unlike the relative
low prevalence of ESA utilization (less than 20%) among
CKD or ESRD patients in the US [20,21], a report from
the Taiwan Department of Health indicated that 85% of
patients with advanced CKD stage 5 not yet requiring dia-
lysis received ESAs therapy in 2012 [22], possibly due to
convenient medical access and minimal financial barrier
of health insurance access in Taiwan. The median he-
matocrit value at the initiation of dialysis was 24.2% (inter-
quartile range 20.6% to 27.5%) in Taiwan [23]. Thus, the
selected cohort in our study is most representative of
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sis in Taiwan.
During the study period, the records of patients receiv-
ing chronic dialysis were extracted from the Registry of
Catastrophic Illness. For catastrophic illnesses such as
ESRD on chronic dialysis, the government registered the
confirmed subjects, after strict verification. After suc-
cessful certification, ESRD patients on chronic dialysis
can be exempted from related medical expenses. There-
fore, the application of catastrophic illness certificate for
ESRD on dialysis required specialist nephrological re-
views in supported medical records, examination reports
and imaging studies after careful exclusion of the causes
of acute renal failure [24].
Outcome measures
The endpoint was all-cause mortality. All subjects were
followed until death or 31 December 2011.
Potential confounders
Baseline demographic data, including age, sex, economic
status and urbanization level of the patients’ places of
residence, were collected. Patients’ systemic health status
was evaluated using the Charlson Comorbidity Index
(CCI). Each increase in the CCI represents a stepwise in-
crease in cumulative mortality, that is, a score of 0 is as-
sociated with a 99% 10-year survival rate and a score of
5 is associated with a 34% 10-year survival rate [25]. The
effect of primary renal disease on survival rate was also
taken into consideration. Data on other comorbidities
that affect survival and are not included in the CCI, such
as diabetes mellitus, hypertension, dyslipidemia, atrial
fibrillation, valvular heart disease, parkinsonism, auto-
immune disease and drug abuse, were also extracted. Pre-
scribed medications that could confound mortality, such
as antiplatelet agents, warfarin, angiotensin-converting en-
zyme inhibitors (ACEIs), angiotensin receptor blockers
(ARBs), beta blockers, calcium channel blockers, diuretics,
nitrate, statins, dipyridamole, steroids, estrogen or proges-
terone, non-steroidal anti-inflammatory drugs, selective
serotonin re-uptake inhibitors, proton pump inhibitors
and oral hypoglycemic drugs, were identified.
Statistical analysis
The baseline characteristics were first analyzed using de-
scriptive statistics and then compared using Pearson χ2
tests for categorical variables, and the independent t-test
and Mann–Whitney U-test for parametric and nonpara-
metric continuous variables, respectively. Cox regression
models were used to calculate hazard ratios (HRs) and
95% confidence intervals (CIs) characterizing the risk
of mortality after chronic dialysis. Because no patient
was undergoing chronic dialysis at the time of enroll-
ment, this variable was calculated as a time-dependentcovariate to ensure that patients were considered at risk
only when they were receiving chronic dialysis. The mo-
dels allowed patients to switch from one exposure group
to another and were adjusted for the variables listed in
Table 1. Subgroup Cox regression analyses were per-
formed to examine the effects of age, sex, CCI, underlying
disease and time cohort on the risk of mortality after
chronic dialysis. Interaction effects were examined using
the likelihood ratio test.
Because the baseline characteristics of patients re-
ceiving chronic dialysis differed substantially from those
receiving conservative care, we also performed a pro-
pensity score–matched analysis. Propensity scores repre-
senting the likelihood of receiving chronic dialysis were
calculated using logistic regression analysis, conditional
on the baseline covariates listed in Table 1. For each
subject who received chronic dialysis, we randomly se-
lected one subject who received conservative care based
on nearest neighbor matching without replacement using
calipers of width equal to 0.1 standard deviation of the
logit of the propensity score. Comparisons of mortality
rates and healthcare costs between groups were per-
formed. Microsoft SQL Server 2012 (Microsoft Corpor-
ation, Redmond, WA, USA) was used for data linkage,
processing and sampling. Propensity score was calculated
using SAS software (version 12.0; SAS Institute, Inc., Cary,
NC, USA). All other statistical analyses were conducted
using STATA statistical software (version 12.0; StataCorp.,
College Station, Texas, USA). Statistical significance was
defined as P <0.05.
Results
Characteristics of the study population
We identified 8,341 older patients with advanced CKD
(estimated GFR <15 ml/min/1.73 m2) who met the in-
clusion criteria between January 2000 and December
2010. The mean age was 79.4 (standard deviation (SD)
7.0) years. Most (55.3%) patients were female, and the
mean CCI was 5.6 (SD 2.1). A plurality of patients had
the following comorbidities: hypertension, diabetes mel-
litus or dyslipidemia. Common concomitant medications
were calcium channel blockers, diuretics, ACEIs or ARBs
and dipyridamole, followed by antiplatelet agents (Table 1).
During the follow-up period, 75.4% of the study sub-
jects (n = 6,292) received chronic dialysis, and the rest
(n = 2,049) received conservative care.
Incidence rate and risk of mortality among older patients
with advanced CKD
A total of 5,807 deaths occurred in older patients with
advanced CKD during the follow-up period of 28,397
person-years. The overall mortality rate was 204.5 per
1,000 person-years. Compared with conservative care,
chronic dialysis was associated significantly with a higher
Table 1 Baseline characteristics of patients
During follow-up period
Parameters All patients Not receiving chronic dialysis Receiving chronic dialysis P
Number of patients 8,341 2,049 6,292
Male, number (%) 3,726 (44.7) 955 (46.6) 2,771 (44.0) 0.042
Age, mean (SD), years 79.4 (7.0) 82.0 (6.4) 78.6 (7.1) <0.001
Follow-up period, mean (SD), days 1,026 (880) 478 (546) 1,205 (894) <0.001
Day of chronic dialysis initiation, median (IQR) - - 192 (90 to 404)
Age at chronic dialysis initiation, mean (SD), years - - 79.4 (7.1)
Monthly income (US$), number (%) 0.158
Dependent 3,395 (40.7) 831 (40.6) 2,564 (40.8)
0 to 637 1,933 (23.2) 505 (24.7) 1,428 (22.7)
637 to 1,400 2,955 (35.4) 703 (34.3) 2,252 (35.8)
>1,400 58 (0.7) 10 (0.5) 48 (0.8)
Urbanization levela, number (%) 0.150
1 4,210 (50.5) 1,021 (49.8) 3,189 (50.7)
2 3,236 (38.8) 800 (39.0) 2,436 (38.7)
3 740 (8.9) 178 (8.7) 562 (8.9)
4 155 (1.9) 50 (2.4) 105 (1.7)
Charlson Comorbidity Indexb, mean (SD) 5.6 (2.1) 5.7 (2.2) 5.5 (2.1) 0.003
Primary renal disease, number (%)
Diabetes 3,070 (36.8) 721 (35.1) 2,349 (37.3) 0.080
Glomerulonephritis 4,008 (48.0) 984 (48.0) 3,024 (48.0) 0.979
Secondary glomerulonephritis/vasculitis 86 (1.0) 26 (1.2) 60 (0.9) 0.220
Hypertension/large vessel disease 986 (11.8) 273 (13.3) 713 (11.3) 0.015
Cystic/hereditary/congenital disease 615 (7.3) 142 (6.9) 473 (7.5) 0.377
Miscellaneous conditions 186 (2.2) 54 (2.6) 132 (2.0) 0.152
Comorbidities, number (%)
Diabetes mellitus 4,807 (57.6) 1,152 (56.2) 3,655 (58.1) 0.137
Hypertension 7,807 (93.6) 1,904 (92.9) 5,903 (93.8) 0.151
Dyslipidemia 3,972 (47.6) 890 (43.4) 3,082 (49.0) <0.001
Atrial fibrillation 579 (6.9) 170 (8.3) 409 (6.5) 0.005
Valvular heart disease 1,698 (20.4) 472 (23.0) 1,226 (19.5) 0.001
Parkinsonism 617 (7.4) 191 (9.3) 426 (6.8) <0.001
Autoimmune disease 1,190 (14.3) 309 (15.1) 881 (14.0) 0.225
Drug abuse 42 (0.5) 13 (0.6) 29 (0.5) 0.335
Concomitant medications, number (%)
Antiplatelet agentsc 1,948 (23.4) 507 (24.7) 1,441 (22.9) 0.087
Warfarin 59 (0.7) 10 (0.5) 49 (0.8) 0.173
ACE inhibitors or ARB 2,716 (32.6) 678 (33.1) 2,038 (32.4) 0.558
Beta blockers 380 (4.6) 83 (4.1) 297 (4.7) 0.207
Calcium channel blockers 4,868 (58.4) 977 (47.7) 3,891 (61.8) <0.001
Diuretics 4,707 (56.4) 1,098 (53.4) 3,609 (57.4) 0.003
Nitrate 1,626 (19.5) 376 (18.4) 1,250 (19.9) 0.132
Statins 710 (8.5) 146 (7.1) 564 (9.0) 0.010
Dipyridamole 2,107 (25.3) 463 (22.6) 1,644 (26.1) 0.001
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Steroids 690 (8.3) 189 (9.2) 501 (8.0) 0.072
Estrogen or progesterone 38 (0.5) 11 (0.5) 27 (0.4) 0.529
Non-steroidal anti-inflammatory drugs 1,248 (15.0) 312 (15.3) 936 (14.9) 0.699
Selective serotonin re-uptake inhibitors 102 (1.2) 28 (1.4) 74 (1.2) 0.496
Proton pump inhibitors 473 (5.7) 157 (7.7) 316 (5.0) <0.001
Oral hypoglycemic drugs 1,843 (22.1) 414 (20.2) 1,429 (22.7) 0.018
aUrbanization levels in Taiwan are divided into four strata according to Taiwan National Health Research Institute publications. Level 1 designates the most
urbanized areas and level 4 designates the least urbanized areas. bThe Charlson Comorbidity Index (CCI) is used to determine overall systemic health. Each
increase in CCI represents a stepwise increase in cumulative mortality.
cIncluding aspirin, clopidogrel, ticlopidine, and cilostazol. ACE, angiotensin-converting
enzyme; ARB, angiotensin II receptor blocker; IQR interquartile range; SD, standard deviation.
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1.49, P <0.001; Table 2). The cumulative incidence of
mortality is illustrated in Figure 1. Other significant risk
factors for mortality among older patients with advanced
CKD included older age (aHR per age 1.07, 95% CI 1.06
to 1.07), male (aHR 1.11, 95% CI 1.05 to 1.17), higher
CCI (aHR per score 1.08, 95% CI 1.07 to 1.10), parkin-
sonism (aHR 1.24, 95% CI 1.13 to 1.37), use of diuretic
(aHR 1.14, 95% CI 1.07 to 1.20) or steroid (aHR 1.11,
95% CI 1.01 to 1.21) (Table 3).
In subgroup analysis, age (P <0.001), hypertension
(P = 0.010) and year of index date (P = 0.027) interacted
significantly with the receipt of chronic dialysis. Com-
pared with conservative care, chronic dialysis increased
mortality risk among patients <80 years old, those with-
out hypertension and those diagnosed with advanced
CKD between 2000 and 2002 (Figure 2).
Healthcare expense in older patients with advanced CKD
undergoing chronic dialysis versus conservative care
During the 28,397-person-year follow-up period, chronic
dialysis was initiated for 6,292 patients at a median of
192 days after enrollment and a mean age of 79.4 (SD
7.1) years. Total healthcare costs, including total hospital
and ambulatory visit costs, were included in our analysis.
Healthcare utilization costs were retrieved primarily
from NHI records, and also from insurance deductible
data. Total healthcare cost categories were dialysis costs,
laboratory and examination fees, medication costs, fees
for procedures or surgery and nurse and physician fees.
The mean healthcare cost for patients receiving chronic
dialysis was US$23,994 (95% CI $23,616 to $24,371) per
person-year; this cost was US$8,738 (95% CI $8,409 to
$9,068) per person-year for the pre-dialysis period and
US$42,980 (95% CI $37,050 to $48,909) per person-yearTable 2 Hazard ratios for mortality according to receipt of ch
Variables Number of deaths Exposure time,patient-years
Not receiving chronic dialysis 1,699 13,071
Receiving chronic dialysisb 4,108 15,326
aAdjusted for all covariates listed in Table 1. bChronic dialysis was calculated as a difor the period after initiation of chronic dialysis. The
mean healthcare cost among the 2,049 patients who
never received chronic dialysis was US$18,252 (95% CI
$16,990 to $19,514) per person-year (Table 4).Propensity score–matched analysis
To further validate the study results, a propensity score
analysis including 1,984 study subjects who received
chronic dialysis and 1,984 matched patients who did not
receive chronic dialysis was conducted. Potentially con-
founding baseline characteristics did not differ signi-
ficantly between these groups [see Additional file 1:
Table S1]. Compared with matched subjects who re-
ceived conservative care, patients who received chronic
dialysis had a significantly increased risk of mortality
(HR 1.16, 95% CI 1.07 to 1.25, P <0.001; Additional file
1: Table S2) and higher total healthcare cost (US$26,273
versus US$17,973 per person-year; P <0.001; Additional
file 1: Table S3).Discussion
This nationwide population-based study provides novel
evidence that dialysis therapy does not always provide a
substantial survival advantage among older patients with
advanced CKD. Most of these patients face the prospect
of dialysis therapy for the remainder of their lives. Thus,
an understanding of the survival benefit of dialysis for
this population is important. Using the initiation of
chronic dialysis as a time-dependent variable in a Cox
regression model, we found that dialysis therapy was as-
sociated with a nearly 40% increase in mortality risk, in
patients ≥70 years old compared with those receiving
conservative care. These increases remained significant
in propensity score-matched analysis.ronic dialysis during follow up
Crude hazard ratio
(95% CI) P value
Adjusted hazard ratioa
(95% CI) P value
(Referent) (Referent)
1.35 (1.26 to 1.44) <0.001 1.39 (1.30 to 1.49) <0.001
screte time-dependent covariate. CI, confidence interval.
Figure 1 Cumulative incidence of mortality among older
patients with advanced chronic kidney disease.
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that of mortality in most older patients with estimated
GFR <15 ml/min/1.73 m2 [26]. Some authors have ar-
gued that older patients may have no real choice in dia-
lysis decision making due to the lack of comprehensive
insurance coverage, which may prohibit access to dialy-
sis through implicit or explicit dialysis rationing due to
limited medical resources and financial barriers [27-29].
Our study results, however, suggest that NHI coverage
of dialysis expenses eliminates financial barriers for pa-
tients who may benefit from the treatment. Furthermore,
nephrologists in Taiwan cannot legally withdraw or with-
hold dialysis without patient agreement, even when they
believe that the treatment will have no benefit or that
any benefit is outweighed by the burdens of treatment.
In other words, patients and their families take active
roles in dialysis decision making. Thus, our findingsTable 3 Significant risk factors for mortality among older
patients with advanced chronic kidney disease
Adjusteda
Variables Hazard ratio (95% CI) P value
Age, per year 1.07 (1.06 to 1.07) <0.001
Male 1.11 (1.05 to 1.17) <0.001
Charlson comorbidity index score,
per 1 point
1.08 (1.07 to 1.10) <0.001
Receiving chronic dialysisb 1.39 (1.30 to 1.49) <0.001
Dyslipidemia 0.86 (0.81 to 0.91) <0.001
Parkinsonism 1.24 (1.13 to 1.37) <0.001
Calcium channel blocker use 0.88 (0.83 to 0.93) <0.001
Diuretic use 1.14 (1.07 to 1.20) <0.001
Dipyridamole use 0.93 (0.88 to 0.99) 0.019
Steroid use 1.11 (1.01 to 1.21) 0.034
aAdjusted for all ovariates in Table 1. bChronic dialysis was calculated as a
discrete time-dependent covariate. CI, confidence interval.provide unrestricted objective evidence that can be used
to optimize the risk-benefit analysis of dialysis therapy in
older patients with advanced CKD.
The survival of patients undergoing dialysis in Taiwan
improved rapidly after the initiation of the NHI program
in 1995. However, outcomes of older patients have not
improved substantially despite public insurance benefits
enabling free healthcare access and total coverage of
medical expenses [30]. Furthermore, Wu and colleagues
[31] found that incident dialysis has been associated with
a 6.27- to 10.4-fold greater risk of mortality in patients
≥70 years old compared with those <30 years old, even
after adjusting for CCI. Among US nursing home resi-
dents, initiation of dialysis was related to substantial
functional decline and up to 60% mortality within one
year [32]. The cost of dialysis care also increases with
age and the number of comorbidities [33]. In our study,
the average annual per-patient cost of dialysis was much
higher than that of conservative care among older pa-
tients; dialysis increased the total cost by US$5,742 per
patient year. The healthcare cost was also significantly
higher after initiation of chronic dialysis than in the pre-
dialysis period (US$42,980 versus US$8,738 per patient
year). In 2011, Medicare expenditures for dialysis in the
US were $71,630 to $87,945 per patient year [1], at least
double the costs calculated in the present study. Thus,
ample opportunity exists to improve the outcomes of
older patients after the initiation of dialysis therapy from
a global standpoint. Alternatively, our findings support
that robust conservative care was encouraged when con-
sidering opportunity cost principles. However, risk-benefit
analysis in the present study is insufficient for decision
making about dialysis for older patients; examination of
this issue requires further long-term assessment.
Most previous small-scale studies [10-12,34,35] found
that dialysis therapy conferred a modest (2 to 45.9 months)
absolute survival advantage over conservative care in older
patients, although this advantage was largely offset by high
comorbidity rates. By contrast, our study demonstrated
that dialysis therapy in older patients increased mortality
risk by almost 40% compared with conservative care. This
discrepancy may be due to differences in enrollment cri-
teria and drawbacks of the statistical methods used in pre-
vious studies, such as the consideration of initiation of
chronic dialysis as a dichotomous (non–time-dependent)
variable in Cox proportional hazards models. This ap-
proach involves the examination of the relationship be-
tween survival and patient characteristics at the time of
study enrollment, which may result in a false increase in
survival rate in the dialysis group because patients who
survived longer had an increased likelihood of receiving
dialysis therapy. Several prognostic models have been de-
veloped to resolve this issue [36-38]. The definition of ini-
tiation of chronic dialysis as a time-dependent covariate in
Figure 2 Subgroup analyses of associations between chronic dialysis and mortality risk among older patients with advanced chronic
kidney disease.
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curves after this event had occurred. This type of model
ensures that the risk of mortality increases only after dialy-
sis initiation, which is more accurate and clinically
relevant.
Our subgroup analyses showed that the risk of mortal-
ity was consistently elevated in older patients receiving
dialysis therapy, regardless of age, sex, comorbidities or
time cohort. Mortality risk was lower in patients >80
years old than in those 70 to 80 years old, implying that
the impact of dialysis on increased mortality risk became
less dominant with advanced age in patients with ad-
vanced CKD. The influence of dialysis on mortality in
very old patients may be offset by competition be-
tween the risks of dialysis and death. The mortality
risk associated with dialysis increased consistently, ir-
respective of specific comorbidities; however, the ad-
justed HR of mortality was lower in patients with, than
in those without, hypertension. This result may be due
to the vulnerability of older patients receiving dialysisto intradialytic hypotension, such that those with higher
blood pressure targets may have a survival benefit [39].
Moreover, the effect of dialysis on mortality risk was
smaller in the 2009 to 2010 cohort than in the 2000 to
2002 cohort. This finding may be attributed to advances
in medical therapy and improvement in dialysis care
over time.
Our study has several strengths. First, we present the
largest currently available database for older patients
with advanced CKD and their dialysis outcomes, with an
extended follow-up period. Second, previous studies
found that late or no referral to a nephrologist may be
associated not only with an increased risk of short-term
mortality, but also with incomplete understanding of
dialysis in decision making [8,34]. Subjects in our study
were referred early to nephrologists, with a median in-
terval of 192 days between enrollment and dialysis. This
characteristic eliminated selection bias because patients
were placed under nephrologists’ care with the intent of
initiating dialysis.
Table 4 Per-person and total costs attributable to advanced chronic kidney disease
Parameters All patients Not receiving chronic dialysis Receiving chronic dialysis
during follow-up period
Number of patients 8,341 2,049 6,292
Age at time of enrollment, mean (SD), years 79.4 (7.0) 82.0 (6.4) 78.6 (7.1)
Total follow-up period, median (IQR), days 759 (302 to 1537) 279 (124 to 613) 985 (475 to 1758)
Day of chronic dialysis initiation, median (IQR) - - 192 (90 to 404)
Age at chronic dialysis initiation, mean (SD), years - - 79.4 (7.1)
Costs during total follow-up period, $US/person-years (95% CI)
Total healthcare cost 22,583 (22,159 to 23,007) 18,252 (16,990 to 19,514) 23,994 (23,616 to 24,371)
Total hospital cost 10,980 (10,553 to 11,407) 14,448 (13,230 to 15,665) 9,850 (9,450 to 10,251)
Total ambulatory visit cost 11,603 (11,444 to 11,763) 3,805 (3,646 to 3,963) 14,143 (13,982 to 14,305)
Costs before chronic dialysis, $US/person-years (95% CI)
Total healthcare cost - - 8,738 (8,409 to 9,068)
Total hospital cost - - 4,450 (4,158 to 4,743)
Total ambulatory visit cost - - 4,287 (4,199 to 4,377)
Costs after chronic dialysis initiation, $US/person-years (95% CI)
Total healthcare cost - - 42,980 (37,050 to 48,909)
Total hospital cost - - 24,333 (18,460 to 30,208)
Total ambulatory visit cost - - 18,646 (18,309 to 18,984)
CI, confidence interval; IQR, interquartile range; SD, standard deviation.
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dialysis decision making among older patients, their fa-
mily members and physicians; however, some limitations
of this study should be acknowledged. First, decisions
about whether to receive dialysis may depend on patient
preferences (family support, financial constraints and the
will to live), but examination of this complex process
was beyond the scope of the current study. Second,
information on several potential confounding factors,
including obesity, nutritional condition, psychosocial
function, performance status and indication for dialysis
initiation, were not available in the NHIRD database.
Estimated GFRs at dialysis initiation were also not re-
corded, whereas the Initiating Dialysis Early and Late
(IDEAL) Study showed no significant survival difference
between early initiation (estimated GFRs: 10.0 to 14.0 ml
per minute) and late initiation (estimated GFRs: 5.0 to
7.0 ml per minute) of dialysis [40]. Third, our study was
subject to the inherent limitations of its retrospective
and observational design. However, randomized control
trials investigating this issue are not possible because of
the potential of violating medical ethics. Finally, we
based the diagnosis of advanced CKD on ESA prescrip-
tions, resulting in the exclusion of patients with ad-
vanced CKD who never received such prescriptions (that
is, those who had no obvious renal anemia). The results
of the study cannot be generalized to all older patients
with advanced CKD.Conclusions
Our findings provide novel information useful for the re-
consideration of dialysis decision making that accounts
for risk-benefit relationships in older patients with ad-
vanced CKD. For frail older patients with late-stage CKD,
conservative care may be a viable treatment option, as dia-
lysis may not prolong life expectancy.
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